Ratings BioNTech SE

Equities

BNTX

US09075V1026

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-07 pm EDT			5-day change	1st Jan Change
100.3 ^USD	-1.44%		-0.26%	-4.93%

08:24am	Indonesia ramps up fight against tuberculosis amid concerns on economic impact	RE
Jun. 05	European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading	MT

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental situation
According to Refinitiv, the company's ESG score for its industry is good.

Strengths

Thanks to a sound financial situation, the firm has significant leeway for investment.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
With an enterprise value anticipated at 4.09 times the sales for the current fiscal year, the company turns out to be overvalued.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Over the past four months, analysts' average price target has been revised downwards significantly.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Over the past twelve months, analysts' opinions have been revised negatively.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
BIONTECH SE	-4.93%	24.21B	B+
VERTEX PHARMACEUTICALS INCORPORATED	+18.72%	125B	B+
REGENERON PHARMACEUTICALS, INC.	+14.19%	108B	B+
ARGENX SE	+0.70%	22.78B	B
GENMAB A/S	-10.86%	17.96B	A-
WUXI APPTEC CO., LTD.	-41.74%	16.43B	A-
BEIGENE, LTD.	-13.31%	16.37B	B
NEUROCRINE BIOSCIENCES, INC.	+2.44%	13.58B	C+
SAREPTA THERAPEUTICS, INC.	+27.89%	11.66B	C+
INSMED INCORPORATED	+83.45%	9.17B	C

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes